Sung-Hack Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11519393/publications.pdf

Version: 2024-02-01

	1163117		1372567	
10	226	8	10	
papers	citations	h-index	g-index	
11	11	11	287	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Archives of Pharmacal Research, 2013, 36, 1185-1188.	6.3	51
2	Pharmacokinetics and pharmacodynamics of LC15â€0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. British Journal of Clinical Pharmacology, 2009, 68, 883-890.	2.4	35
3	Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. Journal of Pharmacy and Pharmaceutical Sciences, 2007, 10, 519.	2.1	31
4	Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: Evidence for multifactorial multidrug resistance. European Journal of Pharmaceutical Sciences, 2006, 29, 102-110.	4.0	30
5	Benzylamine-based selective and orally bioavailable inhibitors of thrombin. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2563-2568.	2.2	27
6	Absorption, metabolism and excretion of [¹⁴ C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Xenobiotica, 2014, 44, 522-530.	1.1	18
7	Fluorobenzamidrazone thrombin inhibitors: Influence of fluorine on enhancing oral absorption. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2483-2486.	2.2	13
8	Noncovalent thrombin inhibitors incorporating an imidazolylethynyl P1. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2775-2778.	2.2	12
9	Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats. Xenobiotica, 2014, 44, 627-634.	1.1	7
10	Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers. Clinical Therapeutics, 2018, 40, 1729-1740.	2.5	2